Pharvaris (PHVS) Stock Price, Quote, News & History

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Name

Revenue

Change

Gross

Change

EBITDA

Change

EBIT

Change

Earnings

Change

About

Sector

Health Care

Industry

Pharmaceuticals

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules,...

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Bulls vs Bears

Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Benzinga

Benzinga

Pharvaris NV (PHVS) Stock Price, Quote, News & History

Key Statistics

Recent Pharvaris NV News

PROPharvaris Publishes Real‑World HAE Study In Clinical Reviews In Allergy & Immunology To Inform On‑Demand Treatment Endpoints

PRORBC Capital Initiates Coverage On Pharvaris with Outperform Rating, Announces Price Target of $52

PROHC Wainwright & Co. Reiterates Buy on Pharvaris, Maintains $60 Price Target

Financials

Cash Flows

Analyst Trends and Forecast

Analyst Rating and Forecast

Valuation Metrics

Company Debt

Key Statistics

About

Edge Rankings

Stock Score Locked: Want to See it?

Compare

FAQ

How do I buy Pharvaris (PHVS) stock?

Who are Pharvaris (PHVS) competitors?

What is the forecast, or price target, for Pharvaris (PHVS) stock?

What is the current price for Pharvaris (PHVS)?

Does Pharvaris (PHVS) pay a dividend?

When is Pharvaris (NASDAQ:PHVS) reporting earnings?

Is Pharvaris (PHVS) going to split?

What sector and industry does Pharvaris (PHVS) operate in?

People Also Watch

Key Statistics

Recent Pharvaris NV News

PROPharvaris Publishes Real‑World HAE Study In Clinical Reviews In Allergy & Immunology To Inform On‑Demand Treatment Endpoints

PRORBC Capital Initiates Coverage On Pharvaris with Outperform Rating, Announces Price Target of $52

PROHC Wainwright & Co. Reiterates Buy on Pharvaris, Maintains $60 Price Target

Financials

Cash Flows

Analyst Trends and Forecast

Analyst Rating and Forecast

Valuation Metrics

Company Debt

Key Statistics

About

Edge Rankings

Stock Score Locked: Want to See it?

Bulls vs Bears

Compare

FAQ

How do I buy Pharvaris (PHVS) stock?

Who are Pharvaris (PHVS) competitors?

What is the forecast, or price target, for Pharvaris (PHVS) stock?

What is the current price for Pharvaris (PHVS)?

Does Pharvaris (PHVS) pay a dividend?

When is Pharvaris (NASDAQ:PHVS) reporting earnings?

Is Pharvaris (PHVS) going to split?

What sector and industry does Pharvaris (PHVS) operate in?

People Also Watch

Bulls vs Bears

PRO
Pharvaris Publishes Real‑World HAE Study In Clinical Reviews In Allergy & Immunology To Inform On‑Demand Treatment Endpoints

PRO
RBC Capital Initiates Coverage On Pharvaris with Outperform Rating, Announces Price Target of $52

PRO
HC Wainwright & Co. Reiterates Buy on Pharvaris, Maintains $60 Price Target

PRO
Pharvaris Publishes Real‑World HAE Study In Clinical Reviews In Allergy & Immunology To Inform On‑Demand Treatment Endpoints

PRO
RBC Capital Initiates Coverage On Pharvaris with Outperform Rating, Announces Price Target of $52

PRO
HC Wainwright & Co. Reiterates Buy on Pharvaris, Maintains $60 Price Target